secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001628280-26-023703
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences terminates HQ lease, separates CEO, CFO, and COO ahead of Aurinia merger
--------------------------------------------------------------------------------

- Lease for ~48,714 sq ft at 4000 Shoreline Court terminated April 1; company pays $2M ( $1.3M cash + $0.7M security deposit).
- CEO Christopher Kirk, CFO Marc Belsky, and COO Mark Schiller enter separation agreements; employment ends at merger close or earlier.
- Kirk receives lump-sum severance of 18 months base salary plus pro-rata bonus; Belsky and Schiller get 12 months COBRA cash payment.
- No disagreements between officers and company; severance contingent on signing general release.
- Merger with Aurinia Pharma U.S. at $6.955/share plus CVR still expected to close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000162828026023703/0001628280-26-023703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000162828026023703/kzr-20260401.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-023703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer